

Innovations in the treatment and management of drug-resistant tuberculosis

Advanced course for TB clinicians

January 24-31, 2024



TIME AND VENUE

This course will be conducted **January 24-31, 2024** (7 working days, including Saturday, 27 January) at the WHO CC Latvia facilities - Tuberculosis and Lung Diseases Center, Riga East University Hospital: Upeslejas, Ropazu district, LV-2118, Latvia

ABOUT THIS COURSE

Exchange of experience course to strengthen the expertise and knowledge of TB specialists in the clinical management of DR-TB, in line with the current TB Action plan for the WHO European Region 2023-2030, as well as emerging approaches and evidence in the programmatic management of DR-TB.

The working language for this course: English

ORGANIZERS

WHO CC Latvia with more than 20 years of experience in facilitating high-quality, evidence-based healthcare personnel capacity-building activities, that are based on scientific advances, WHO and regional guidelines, and practical aspects in the treatment and management of DR-TB



Online registration & course details are available on our website:
<http://www.tblatvia.com/tb-training-2024/>

Innovations in the treatment and management of drug-resistant tuberculosis

January 24-31, 2024

WHO CC Latvia, Tuberculosis and Lung Diseases Center, Riga East University hospital



REGISTRATION, FEE AND LOGISTICS

REGISTRATION

- The registration deadline for this course is **December 12, 2023**.
- Online registration & course details are available on our website: <http://www.tblatvia.com/tb-training-2024/>

FEE

- The tuition fee - 1600 EUR per participant, covering: training materials, field visits, lunches and coffee breaks on working days/working hours, local transfers, and visa invitation support.
- In addition to the tuition fee participants should cover their international flight, hotel accommodation, visa, and other personal expenses.

LOGISTIC SUPPORT

- WHO CC Latvia ensures full logistic support to participants - including accommodation, local transfers, catering, and visa invitation support.

Contact information:

- **Course director Dr. Liga Kuksa,** ligakuksa@gmail.com;
- **Course coordinator Liga Rusmane,** liga.rusmane@gmail.com; t. +371 29774267

PROVISION OF THE COURSE

- This 7-day advanced course for TB clinicians is designed to integrate the most recent DR-TB guidelines, recommendations and research evidence on clinical and programmatic management of DR-TB with intensive fieldwork - interactive case analysis, study visits, group discussions and presentations.
- The program covers field visits to the TB facilities of the TB and Lung Diseases Center of Riga East University Hospital, as well as study visits to the local NGOs/social/healthcare organizations providing services to TB patients.
- The faculty of WHO CC Latvia involves more than 20 experts, clinicians, scientists, researchers, nurses, and other public health sector staff engaged in TB care.
- Training is delivered in collaboration with international experts and organizations covering specific areas of expertise.




Dr. Liga Kuksa
Head of WHO CC Latvia



We are delighted that colleagues from other countries choose to visit the Latvian WHO CC to broaden their professional expertise and knowledge, which makes an important contribution to our work.

A common approach to translating TB innovations into clinical practice, sharing experiences and collaborating across countries is essential to ensure the success of TB programs and to continuously improve the quality and continuity of patient care.



Innovations in the treatment and management of drug-resistant tuberculosis

aslimnica
RIGA EAST UNIVERSITY HOSPITAL

January 24-31, 2024



COURSE CONTENT

This 7- days course curriculum covers following modules:

- WHO Global strategies and targets for TB prevention, treatment and control.
- Epidemiology of TB, M/XDR-TB and TB/HIV globally and in the WHO European Region.
- Rapid tests for diagnosis of TB and DR-TB. Diagnostic algorithms.
- Interpretation of genotypic drug-susceptibility results (including WGS).
- Risk of development, pathogenesis, diagnosis, and treatment of *M.tuberculosis* infection.
- Treatment of Isoniazid - susceptible TB.
- Drugs used for the treatment of TB and TBI.
- Consolidated guidelines for the treatment of RR-TB.
- DR-TB regimen selection and design.
- Management of D/XDR-TB in special situations.
- Treatment and management of drug-susceptible and DR-TB in children.
- TB diagnosis and treatment for HIV co-infected patients.
- Chronic viral hepatitis C: Treatment possibilities for both diseases at once.
- Surgical treatment of pulmonary TB and M/XDR-TB.
- Management of adverse events in DR/RR-TB treatment.
- Pharmacovigilance. aDSM.
- Monitoring of the treatment effectiveness.
- Monitoring and evaluation. Treatment outcome definitions.
- The role of operational research in the TB programs.
- Nontuberculous Mycobacterial Pulmonary Disease.
- Extrapulmonary tuberculosis.
- Principles of out-patient treatment, its possibilities.
- DOT vs VOT.
- Systematic screening of contacts and high-risk groups.
- Developing models of integrated and person-centered care for DR-TB patients.
- The role of operational research in the TB programs.
- Effective Communication for healthcare workers working with TB.
- Systematic screening for TB.
- Fundamentals of infection control for TB. FAST Strategy.
- Palliative care.
- Post - TB Lung disease.



The program covers field visits to the TB facilities of the TB and Lung Diseases Center of Riga East University Hospital:

- DR-TB department,
- National TB Reference Laboratory,
- Overview of the infection control measures at the TB facilities,
- Riga TB Outpatient department - covering the practical aspects of the organization of psychosocial care for TB patients, directly observed and video observed TB treatment, and sputum sample collection.
- Local NGOs/social/healthcare organizations providing services to TB patients

Online registration & course details are available on our website:
<http://www.tblatvia.com/tb-training-2024/>